TPCA-1, >=95% (HPLC), powder

TPCA-1, >=95% (HPLC), powder

Application

TPCA-1 has been used to study its cytotoxic effects in RPMI8226 and LP1 cell lines. It has also been used as a culture media supplement for nuclear protein fractions extracted from human airway smooth muscle cells.

Biochem/physiol Actions

TPCA-1 is a potent and selective inhibitor of human IκB kinase-2 (IKK-2) with IC50 = 17.9 nM for IKK-2 compared to 400nm for IKK-1. It has been used to study inhibition of IKK-2 to prevent inflammatory mediator release in animal models of arthritis and airway inflammation.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

1, 5 mg in glass bottle

Preparation Note

TPCA-1 is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml. It is insoluble in water.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3576969 TPCA-1, >=95% (HPLC), powder white to light brown 100 SAYGKHKXGCPTLX-UHFFFAOYSA-N 1S/C12H10FN3O2S/c13-7-3-1-6(2-4-7)9-5-8(10(14)17)11(19-9)16-12(15)18/h1-5H,(H2,14,17)(H3,15,16,18) SIGMA-ALDRICH powder ≥95% (HPLC)
£218.68 (exc VAT) per 1MG
-
+
3576970 TPCA-1, >=95% (HPLC), powder white to light brown 100 SAYGKHKXGCPTLX-UHFFFAOYSA-N 1S/C12H10FN3O2S/c13-7-3-1-6(2-4-7)9-5-8(10(14)17)11(19-9)16-12(15)18/h1-5H,(H2,14,17)(H3,15,16,18) SIGMA-ALDRICH powder ≥95% (HPLC)
£852.43 (exc VAT) per 5MG
-
+